ANDA 214879, held by Micro Labs. Succinylcholine Chloride.
As of Nov 16, 2026, ANDA 214879 (Succinylcholine Chloride), held by Micro Labs, was first approved by FDA on Nov 24, 2020, with 3 approved supplements and 0 published complete response letters.
Succinylcholine chloride injection is indicated in adults and pediatric patients: as an adjunct to general anesthesia to facilitate tracheal intubation to provide skeletal muscle relaxation during surgery or mechanical ventilation.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 24, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Succinylcholine Chloride20MG/ML · injectable;injection | Succinylcholine Chloride | Rx |
| Feb 22, 2023 | Supplement 6Labeling · Standard review | Approved | None posted |
| Mar 31, 2022 | Supplement 4Labeling · Standard review | Approved | None posted |
| Mar 31, 2022 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 24, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters